Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $115.3K | $9.1K | $9.8K | $3.2K | $268.2K | $3.4K | $42.0K | $0 |
| Cost of revenue | $0 | −$112.3K | $0 | $0 | $49.3K | $743 | $557 | $0 |
| Gross profit | $115.3K | $121.4K | $9.8K | $3.2K | $218.9K | $2.7K | $41.5K | $0 |
| Gross margin | 100.0% | 1333.4% | 100.0% | 100.0% | 81.6% | 78.2% | 98.7% | — |
| R&D | $4.4M | $3.4M | $3.3M | $2.4M | $1.6M | $1.5M | $1.3M | $739.0K |
| Operating income | −$5.3M | −$4.2M | −$4.1M | −$3.1M | −$2.3M | −$2.4M | −$2.1M | −$2.2M |
| EBITDA | −$3.3M | −$2.6M | −$2.5M | −$1.8M | −$1.3M | −$1.5M | −$1.3M | −$2.2M |
| Net income | −$4.1M | −$374.5K | −$3.2M | −$968.5K | −$1.5M | −$2.0M | −$2.1M | −$2.1M |
| Net margin | -3548.1% | -4113.0% | -32565.9% | -30570.4% | -544.6% | -57483.1% | -5016.3% | — |
| EPS (diluted) | -0.07 | -0.01 | -0.05 | -0.02 | -0.02 | -0.02 | -0.02 | -0.01 |
Annual figures · source: Financial Modeling Prep
No one on the platform currently holds LVCLY.
No tracked institution reports a position in LVCLY as of their last filing.
No one on the platform has traded LVCLY yet.
| $13M |
| — |
| EIGRQEiger BioPharmaceuticals, Inc. | $8.50 | +6.25% | $13M | — |
| LXXGFLexaGene Holdings Inc. | $0.08 | +0.00% | $11M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.